pillbase.ru

Kyprolis

Active substance: carfilzomib

carfilzomib

Centralised EU authorisationActive

Marketing holder: Amgen Europe B.V.

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 3
  • KYPROLIS
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · CARFILZOMIB 30 mg/15mL
    76075-102
    Onyx Pharmaceuticals, Inc.
  • KYPROLIS
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · CARFILZOMIB 10 mg/5mL
    76075-103
    Onyx Pharmaceuticals, Inc.
  • KYPROLIS
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · CARFILZOMIB 60 mg/30mL
    76075-101
    Onyx Pharmaceuticals, Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-309a-78a9-98dd-5248d3a20734,01a12099-f44f-7d80-881b-58c67ce0ca69,01a1209c-2b0e-7602-b514-8163c23dfb89;count=3 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/003790
Registration status
Active
ATC code
L01XX45
Sources
  • product · EMA · EMEA/H/C/003790 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/003790 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/003790 · Verified 2026-10-09